Search

Please note

Due to the recent spike in Covid-19 cases, we are no longer able to entertain walk-in visits to our headquarters or any of our facilities.

×

Dexzidine MR modified-release tablets

Dexa Medica

Product packaging may vary from one country to another.

Ingredients in every modified-release tablet

Trimetazidine 35 mg

Each package contains

3 strips of 10 modified-release tablets

Other details

Dosage formTablet; coated; modified-release
Flavour None

W.H.O. classification

ATC Level 1 C - Cardiovascular system
ATC Level 2 C01 - Cardiac Therapy Drugs
ATC Level 3 C01E - Other Cardiac Preparations in ATC

Warnings

Pregnancy

NOT RECOMMENDEDThis item is not safe for use during pregnancy.

Lactation

NOT RECOMMENDEDThis item is not safe for use during lactation.

Alcohol

CONSULT YOUR DOCTORSafety of this item for use with alcohol has not been established. Please consult your doctor.

Machinery

CONSULT YOUR DOCTORSafety of this item for use while operating heavy machinery has not been established. Please consult your doctor.

Available in

Cambodia

Dosage information

FOR ALL AGES
One tablet in the morning and evening, to be taken at meal times.

PATIENT WITH RENAL IMPAIRMENT
Not recommended if the creatinine clearance is lower than 15 ml/minute.

Indication

Adjunctive to established anti-angina. It should not be used as monotherapy.

Back to products

Email

info@dexagroup.com

Phone

+62 21 7454-111

Share this webpage

Address

Titan Center, 3rd Floor,
Jalan Boulevard Bintaro,
Block B7/B1 No. 5,
Bintaro Jaya, Sector 7,
Tangerang 15224, Indonesia

Dexagroup, Titan Center

Terms and Conditions

By accessing and using this website, you agree to the terms and conditions that have been set forth by us. Please read our full Terms and Conditions, including our Privacy Policy, for details. We comply with the General Data Protection Regulation (GDPR) of the European Union.

Pharmacovigilance

It is crucial for patients and healthcare practitioners to report any adverse reactions to any medical product. This helps improve public health and safety, and enables researchers and manufacturers to accurately evaluate the benefit / risk balance of our medical products.

In case you experience any suspected adverse reaction or unexpected side-effect as a result of our medication, please reach us at +62 21 7454-111 (during working hours) or pv@dexagroup.com. For emergency assistance, please contact your healthcare practitioner immediately.

Accuracy

Considerable effort has been made to ensure that the information provided on this website is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive, and may become out-of-date or inaccurate without warning. Information is intended only to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service. The provided information is a supplement to, and NOT a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

Medication

The absence of a warning for a given drug or drug combination should in no way be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Dexagroup or any related person or entity does not assume any responsibility for any aspect of healthcare administered with the aid of information on this website. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, or if you need medical assistance, please check with your doctor, nurse or pharmacist immediately.